{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-22-000030","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.963903+00:00","generated_at":"2026-06-22T04:10:54.793543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pliant Therapeutics Q3 loss $30.6M; positive Phase 2a IPF data; $215M offering closed","bullets":["Net loss of $30.6M in Q3 2022 vs $27.0M prior year; cash & investments $360.2M, funding to mid-2025.","Positive Phase 2a data for bexotegrast in IPF: dose-dependent improvement in FVC, QLF, and biomarkers over 12 weeks.","Closed public offering yielding $215.4M net proceeds to fund clinical programs and operations.","Appointed Dr. Katharine Knobil to Board; oncology IND submission expected by end of 2022.","DSMB reviews for INTEGRIS-IPF and INTEGRIS-PSC trials recommended continuation without modification."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-22-000030","json":"https://secwatch.observer/filing/0001746473-22-000030.json","markdown":"https://secwatch.observer/filing/0001746473-22-000030.md","text":"https://secwatch.observer/filing/0001746473-22-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647322000030/0001746473-22-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647322000030/plrx-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:10:54.793543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4999df474e7017e9dc70602674cf60af75f9729","claim":"PLIANT THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"Pliant Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647322000030/0001746473-22-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}